Fast-Track Reciprocal Drug Approval

Summary#

The FAIR Act creates a new fast-track pathway in the Federal Food, Drug, and Cosmetic Act for certain drugs and biological products that are already authorized for marketing by specified foreign regulators. A sponsor can request "reciprocal marketing approval" if the product is lawfully marketed by a trusted international regulatory authority, is intended for an immediately life‑threatening disease or condition, and is not already approved here. The request must include documentation and English translations of the foreign dossier. The Secretary of Health and Human Services must grant or deny the request within 30 days, finalize labeling and any required postmarket studies during that time, and may treat the request as an approval under existing U.S. approval pathways. The Secretary can withdraw or suspend reciprocal approval if new evidence shows serious safety risks or if the foreign regulator withdraws its authorization. The bill also allows manufacturers to seek reciprocal allowance to conduct clinical investigations authorized by trusted foreign regulators, with a 30‑day decision timeline. The European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency, and Health Canada are listed as "trusted" authorities, and the Secretary can add others. The Secretary must report to congressional committees after 5 years on the program's use and effects.

What it means for you#

  • Patients with immediately life‑threatening conditions could see certain foreign‑authorized drugs become available here faster if sponsors apply under this pathway.
  • Drug makers can submit foreign authorization dossiers (with English translations) to request fast reciprocal approval or to request permission to run clinical trials here that match trials already authorized abroad.
  • The agency must decide on requests within 30 days and set labeling and postmarket study requirements in that period.
  • The agency may withdraw approvals if new safety information emerges or if the foreign regulator revokes its authorization; it may phase out approvals to protect patients.

Expenses#

No publicly available information on overall federal costs or estimated budget effects is included in the bill text. The bill does state that a request for reciprocal marketing approval is to be treated as an application for fee purposes under chapter VII, meaning sponsors may be charged fees the same way they are for existing application types.

Proponents' View#

The bill's findings state supporters believe reciprocal approval will accelerate patient access to innovative therapies for life‑threatening diseases, increase U.S. patient participation in clinical research, and help preserve U.S. competitiveness in biomedical innovation by recognizing approvals from trusted foreign regulators.

Opponents' View#

No publicly available information on opponents' views or formal objections is included in the bill text or metadata provided.